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Pharmacists were instructed to ask each person dropping off or picking up a prescrip-
tion about concurrent NHP-drug use, and the occurrence of any potential AE. Tele-
phone interviews conducted by a study team member were used to follow up if an AE 
was reported. Up to three months of active surveillance was planned in ten community 
pharmacies in Ontario. All cases were independently adjudicated for causality, serious-
ness and outcome by 2 study team members with expertise in NHPs. Algorithms used 
for adjudication included the WHO guidelines, Naranjo causality scale, and Horn 
algorithm (drug interaction probability scale). RESULTS: Over 2000 patients have 
been screened. A total of 759 reported taking NHPs and drugs concurrently, 35 were 
identiﬁed as having suspected AEs, and 15 consented to, and were available for, an 
in-depth interview. Two not previously described probable NHP-drug interactions 
have been identiﬁed including analysis of their purported CYP450 pharmacokinetic 
mechanisms. In case 1, strong sedation occurred after concomitant intake of citalo-
pram, nortriptyline, oxycodone, and melatonin. Melatonin was shown to inhibit 
CYP2C19 and thus citalopram metabolism. In case 2, heart palpitations occurred after 
concomitant intake of two NHPs containing a variety of active substances and pro-
gesterone cream use. Laboratory analyses to investigate possible mechanisms to 
explain the clinical symptoms described is ongoing. CONCLUSIONS: In this study, 
the rate of AEs suspected to be related to NHP use was 5.7%. Active surveillance of 
NHP-drug interactions and NHP-related AEs in community pharmacies is feasible and 
provides an effective way to discover unknown pharmacokinetic and pharmacody-
namic NHP-related interactions.
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OBJECTIVES: Along with neutropenia and anemia, thrombocytopenia is one of the 
most common hematological complications of cancer treatment. Prolonged/severe 
thrombocytopenia increases the risk of bleeding. The goal of this study was to evalu-
ate the epidemiology of thrombocytopenia among cancer patients on chemotherapy. 
METHODS: Data were collected between 2000–2007 from a large electronic 
medical records database in 18 outpatient oncology clinics throughout the US. Adult 
patients with NSCLC, breast, ovarian, H&N, and colorectal cancers were of inter-
est. Chemotherapy regimens were grouped into platinum-, anthracycline-, gem-
citabine-, and taxane- based. Thrombocytopenia (150,000 Ml) prevalence was 
examined by tumor and regimen type. RESULTS: A total of 47,159 patients [mean 
age 61, male 42%] and 75,243 chemotherapy regimens were analyzed. Breast cancer 
patients constituted 19.5%, followed by NSCLC (14.9%), colorectal (11.9%), 
ovarian (3.1%), and H&N (2.5%). Platinum-based regimens accounted for 27.8% 
of all regimens. Prevalence of post-chemo thrombocytopenia was highest among 
gemcitabine treated patients (64.2%), followed by platinum (55.5%), and lowest 
with taxane-based regimens (21.9%). Most of the patients across all treatment 
regimen groups presented with thrombocytopenia (grade 1). Eleven percent of 
patients on platinum and gemcitabine regimens, 2% in taxane-treated patients, and 
5% in anthracycline-treated patients had PC  50 r 109/L (grade 3–4). Patients with 
NSCLC and ovarian cancer had the highest incidence of thrombocytopenia. A sub-
stantial proportion of patients, 30% developed both anemia and thrombocytopenia 
after chemotherapy start. More than 90% of patients with thrombocytopenia grade 
1–3 also had anemia grade 1 or 2. Twenty percent of those with grade 4 thrombocy-
topenia presented with anemia grade 3–4. Of these, 16.7% had NSCLC, 16.2% 
were breast cancer patients, and 9.1% were colorectal cancer patients. Platelet trans-
fusions were rare (5% of all chemotherapy-treated patients). CONCLUSIONS: 
Thrombocytopenia was common in this large cohort of cancer patients on 
 chemotherapy. A substantial proportion of patients developed both anemia and 
thrombocytopenia.
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OBJECTIVES: Cancer patients receiving chemotherapy may often require chemo-
therapy dose delays and dose reductions due to chemotherapy-induced side effects 
such as thrombocytopenia, neutropenia, and anemia. In responsive cancers, such dose 
delay and dose reduction of chemotherapy may be associated with decreased effective-
ness and poorer clinical outcomes. In this study, we analyzed the characteristics of 
dose delay among cancer patients on chemotherapy. METHODS: Data from 2000–
2007 from a large electronic database of outpatient oncology clinics in the US were 
analyzed. Adult patients with a cancer diagnosis and complete chemotherapy plan 
information were eligible for this analysis. Chemotherapies were grouped into plati-
num-, anthracycline-, gemcitabine-, taxane-based, and other. The planned cycle dura-
tion was compared to the actual duration. A difference of more than 7 days was 
deﬁned as a cycle delay. RESULTS: The dataset included 47,159 cancer patients (mean 
age 61 (SD 13), male 42%) and 75,243 chemotherapy regimens. A total of 26,317 
patients (113,175 chemo cycles) had complete chemotherapy plan information. Of 
these, 5961 (22.7%) experienced chemo delays in 9293 cycles (8%) during chemo-
therapy. The average length of delay was 17 days (SD, 8 days; median, 14 days); 25% 
of the delays were more than 3 weeks. Tumor types of the 5,961 patients with cycle 
delays included, colorectal cancer (20.3%), NSCLC (18.6%), breast cancer (15.2%), 
ovarian (4.4%), and H&N (2.9%). The reasons for delaying chemo were not speciﬁed 
in the database. However, many (60%) experienced anemia (Hb  11 g/dL) or throm-
bocytopenia (150,000 Ml, 62%) at some point during chemotherapy. CONCLU-
SIONS: Chemotherapy cycle delays were relatively common in this large group of 
cancer patients. While decisions to delay therapy were multi-factorial, further research 
is needed to investigate the reasons, preventable measures, clinical and cost outcomes 
of these delays.
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OBJECTIVES: As comorbidity has a direct impact on choice of cancer treatment and 
patient prognosis after diagnosis, this study compared the prevalence and incidence 
of comorbidity among head and neck cancer (HNC) patients to a cancer-free popula-
tion in the Netherlands. METHODS: Patients diagnosed with oral cavity, pharynx 
(excluding nasopharynx), and larynx cancer between 2000–2006 were selected from 
the PHARMO RLS and Eindhoven Cancer Registry. Each HNC patient was matched 
by age and gender to four cancer-free controls selected from the PHARMO RLS with 
date of cancer diagnosis selected as the index date for both cohorts. Comorbidities 
including diabetes, cardiovascular disease (CVD), anaemia, asthma/COPD, pneumo-
nia, and depression were identiﬁed by prescription and/or hospitalisation data. Preva-
lence ratios and hazard ratios (HRs) were used to compare the occurence of events 
before and after diagnosis, respectively. RESULTS: Patients diagnosed with oral 
cavity, pharynx (excluding nasopharynx), and larynx cancer between 2000–2006 were 
selected from the PHARMO RLS and Eindhoven Cancer Registry. Each HNC patient 
was matched by age and gender to four cancer-free controls selected from the 
PHARMO RLS with date of cancer diagnosis selected as the index date for both 
cohorts. Comorbidities including diabetes, cardiovascular disease (CVD), anaemia, 
asthma/COPD, pneumonia, and depression were identiﬁed by prescription and/or 
hospitalisation data. Prevalence ratios and hazard ratios (HRs) were used to compare 
the occurence of events before and after diagnosis, respectively. CONCLUSIONS: 
HNC patients suffer from signiﬁcantly higher prevalence and incidence of both chronic 
and acute comorbidies, compared to cancer-free controls. These conditions may affect 
patient eligibity for aggressive treatment and place them at higher mortality risk.
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OBJECTIVES: Bisphosphonate-associated osteonecrosis of the jaw (BONJ) is a com-
plication of long-term bisphosphonate (BP) use. Given the beneﬁcial effects of BP on 
bone quality in patients with cancer or osteoporosis, it is of great importance to review 
the risk as it relates to time-to-event or the cumulative dose until the onset of the 
disease. METHODS: Here, we report on a review of 71 case series published since 
2003. We calculated the weighted means of time to event, as well as the minimum 
reported time and dose for zoledronate, pamidronate, and oral bisphosphonates. 
RESULTS: The mean time to BONJ after zoledronate treatment was calculated at 1.8 
years and the minimum was 10 months; after pamidronate the mean time was 2.8 
years and the minimum was 18 months; and after oral BP therapy the mean time was 
4.6 years and the minimum was 3 years. CONCLUSIONS: Zoledronic acid seems to 
be the most potent among the N-containing BPs. Factors that seem to affect BONJ 
and time to event were invasive dental procedures, and other comorbid factors such 
as increased age, rheumatoid arthritis, diabetes, use of corticosteroids, Vitamin D 
deﬁciency, and more. Understanding the pathophysiology of the disease requires 
further research.
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OBJECTIVES: To study occurrence of thromboembolic (TE) events before and after 
RCC diagnosis compared to cancer-free controls as this information is lacking in 
published literature. METHODS: RCC patients were selected from PALGA, a Dutch 
pathology database, and linked to the PHARMO record linkage system (PHARMO 
RLS) which includes drug use and hospitalization data in the Netherlands. RCC 
